製薬業界におけるESGの動向

当レポートでは、製薬業界におけるESGの動向を調査し、製薬業界の現況、製薬業界における主な汚染の原因、汚染の影響、ESGコンプライアンスに向けた製薬業界の取り組み、ESGの実施に関連する成長機会と課題、ケーススタディなどをまとめています。

目次

第1章 イントロダクション

第2章 製薬業界の概要

• 製薬業界のサプライチェーン
• 医薬品サプライチェーンにおけるESGの阻害要因

第3章 製薬産業の環境への影響

• 医薬品汚染の主な原因
• 医薬品汚染の影響
• Scope3への関心の高まり

第4章 製薬業界におけるESG

• ESGの概要
• さまざまな業界でESGの採用が増加
• 5つの重要な方法におけるESGの提案
• 製薬業界におけるESGの業績
• 製薬業界におけるESG投資の急増
• 主要企業によるESG投資
• バリューチェーンにESGを組み入れている企業

第5章 市場力学

• 製薬業界におけるESG市場のマクロ経済動向
• 製薬業界のESG関連の推進因子
• 製薬業界のESG関連の課題
• 製薬業界におけるESG関連の機会

第6章 付録：頭字語

List of Tables

• Table 1 : Net-Zero GHG Commitments by Major Life Sciences Companies
• Table 2 : Environmental, Social and Governance Factors in the Pharmaceutical Industry
• Table 3 : ESG Factors in the Pharmaceutical Industry
• Table 4 : Key Environmental, Social and Governance Issues in the Pharmaceutical Industry
• Table 5 : ESG Ranking of Pharmaceutical Industry Players, 2022
• Table 6 : Acronyms Used in This Report

List of Figures

• Figure 1 : Global Market Shares of the Pharmaceutical Industry, by Region, 2021
• Figure 2 : Top 10 Global Pharmaceutical Companies, by Revenue, 2021
• Figure 3 : Pharmaceutical Supply Chain
• Figure 4 : Level of Adoption of ESG across All Industries
• Figure 5 : Level of Adoption of ESG across All Industries by Region, 2021 and 2022

Highlights:

This report provides a review of ESG trends in the pharmaceutical market, focusing on current trends and developments. The report will have a detailed analysis of key opportunities that would help in the market growth. It will also analyze the major challenges faced by pharmaceutical manufacturers and industry players.

Report Scope:

The report will provide an outline of the global pharmaceutical industry and an ESG overview of the pharmaceutical industry. Qualitative insights on ESG trends and their impact on pharmaceutical manufacturers are provided, along with a detailed analysis of the pharmaceutical industry supply chain with regard to ESG. The report explains the primary drivers, challenges and trends influencing ESG implementation in the pharmaceutical industry.

Report Includes:

• A brief general outlook of the ESG trends in pharmaceutical industry
• Detailed information about ESG-related developments in the pharmaceutical industry and analyses of factors affecting ESG applications
• Discussion of current trends and issues in the pharmaceutical industry, with emphasis on major challenges and opportunities
• Analysis of the whole supply chain of the pharmaceutical industry and its association with ESG
• Information on major causes, and impact of pharmaceutical pollution and a detailed case study related to pharmaceutical pollution

Table of Contents

Chapter 1 Introduction

• 1.1 What is Environmental, Social and Governance (ESG) Compliance?
• 1.2 Study Goals and Objectives
• 1.3 Reasons for Doing This Study
• 1.4 Scope of Report
• 1.5 Intended Audience
• 1.6 Information Sources
• 1.7 Analyst's Credentials
• 1.8 BCC Custom Research
• 1.9 Related BCC Research Reports

Chapter 2 Overview of the Pharmaceutical Industry

• 2.1 Introduction
• 2.2 Pharmaceutical Industry Supply Chain
  • 2.2.1 Manufacturing
  • 2.2.2 Distribution
  • 2.2.3 Providers
  • 2.2.4 Customers and Patients
• 2.3 ESG Deterrents in the Pharmaceutical Supply Chain

Chapter 3 Environmental Impact of the Pharmaceutical Industry

• 3.1 Introduction
• 3.2 Major Causes of Pharmaceutical Pollution
  • 3.2.1 Drug Use, Ingestion and Disposal
  • 3.2.2 Healthcare Institutions
  • 3.2.3 Drug Manufacturers
  • 3.2.4 Agriculture and Argo-Products
  • 3.2.5 Local Pharmaceutical Use and Disposal in Humans
• 3.3 Impact of Pharmaceutical Pollution
  • 3.3.1 Effects on Aquatic Life and Fish
  • 3.3.2 Disrupting Normal Sewerage Process Operations
  • 3.3.3 Drinking Water Impact
  • 3.3.4 Long-Lasting Effects on the Environment
  • 3.3.5 Antibiotic Resistance
  • 3.3.6 Impact on Wildlife
• 3.4 Growing Focus on Scope 3 Emissions
  • 3.4.1 Case Study on Pharmaceutical Pollution

Chapter 4 ESG in the Pharmaceutical Industry

• 4.1 Introduction to ESG
• 4.2 Increasing Adoption of ESG across Various Industries
• 4.3 ESG Proposition in Five Critical Ways
• 4.4 ESG Performance in the Pharmaceutical Industry
• 4.5 Surge in Investment in ESG in the Pharmaceutical Industry
• 4.6 ESG Investments by Key Players
• 4.7 Companies Incorporating ESG into Their Value Chains
  • 4.7.1 Biogen
  • 4.7.2 Collaboration between Novartis and GSK in Africa
  • 4.7.3 Amgen
  • 4.7.4 Enabler

Chapter 5 Market Dynamics

• 5.1 Macroeconomic Trends in the Market for ESG in the Pharmaceutical Industry
  • 5.1.1 Climate Change
  • 5.1.2 Medication Access in Underdeveloped Nations
  • 5.1.3 Drug Pricing and Gouging
• 5.2 ESG-Related Drivers of the Pharmaceutical Industry
• 5.3 ESG-Related Challenges for Pharmaceutical Industry
• 5.4 ESG-Related Opportunities in the Pharmaceutical Industry

Chapter 6 Appendix: Acronyms